Tenaya Therapeutics, Inc.
NASDAQ: TNYA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Faraz Ali
- Employees
- 70
- Headquarters
- South San Francisco, United States
- IPO year
- 2021
- Market cap
- $121.8M
- Website
- https://www.tenayatherapeutics.com
Loading TNYA…
Loading profile data…Frequently asked questions about TNYA
What does Tenaya Therapeutics, Inc. (TNYA) do?
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for pla...
Where does TNYA trade?
Tenaya Therapeutics, Inc. (TNYA) trades on the NASDAQ.
What sector is TNYA in?
Tenaya Therapeutics, Inc. (TNYA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tenaya Therapeutics, Inc.?
Faraz Ali is the chief executive officer of Tenaya Therapeutics, Inc. (TNYA).
Where is Tenaya Therapeutics, Inc. headquartered?
Tenaya Therapeutics, Inc. is headquartered in United States.
Does TNYA pay a dividend?
Tenaya Therapeutics, Inc. (TNYA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TNYA go public?
Tenaya Therapeutics, Inc. (TNYA) completed its initial public offering in 2021.